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ABSTRACT 
Occipital nerve stimulation (ONS) is a promising treatment for refractory chronic headache 
disorders but is invasive and costly.  Identifying predictors of response would be useful in 
selecting patients.  We present the results of an open-label prospective cohort study of 100 
patients (35 chronic migraine, 33 chronic cluster headache, 20 short-lasting unilateral 
neuralgiform headache attacks and 12 hemicrania continua) undergoing ONS using a 
multivariate binary regression analysis to identify predictors of response. 
Response rate of the cohort was 48%.  Multivariate analysis showed short lasting unilateral 
neuralgiform headache attacks (OR 6.71; 95% CI 1.49-30.05; p=0.013) and prior response 
to greater occipital nerve block (OR 4.22; 95% CI 1.35-13.21; p=0.013) were associated 
with increased likelihood of response.  Presence of occipital pain (OR 0.27; 95% CI 0.09-
0.76; p=0.014) and the presence of severe anxiety and/or depression (as measured on hospital 
anxiety and depression score) at time of implantation (OR 0.32; 95% CI 0.11-0.91; p=0.032) 
were associated with reduced likelihood of response. 
Possible clinical predictors of response to ONS for refractory chronic headaches have been 
identified.  Our data shows that those with short-lasting unilateral neuralgiform headache 
attacks respond better than those with chronic migraine and that a prior response to greater 
occipital nerve block is associated with positive outcomes.  This study suggests that the 
presence of occipital pain and severe mood disorder at time of implant are both associated 
with poor outcomes to ONS. 
  
4 Miller 
 
 
 
INTRODUCTION 
Occipital nerve stimulation (ONS) is a promising treatment for medically refractory chronic 
headache disorders. Open-label studies have demonstrated possible efficacy in chronic 
migraine (CM), chronic cluster headache (CCH), hemicrania continua (HC)  and short 
lasting unilateral neuralgiform headache attacks (short lasting unilateral neuralgiform 
headache attacks with conjunctival injection and tearing [SUNCT] and short lasting 
unilateral neuralgiform headache attacks with autonomic features [SUNA]).1-7  However, 
the results from a small number of controlled trials in CM have been disappointing.  The 
ONSTIM (Occipital Nerve Stimulation for the Treatment of Chronic Migraine Headache) 
study reported a positive effect of ONS with a 50% reduction in headache frequency or a 
three-point reduction in pain score in 39% of the active group compared to 6% in a sham-
stimulation group. 8  The PRISM (Precision Implantable Stimulator for Migraine) study 
failed to find a difference in the reduction of migraine days between active and sham-
stimulation groups in a group including treatment refractory chronic migraine patients. 9  A 
randomized double-blind study by Silberstein et al. (The St Jude Medical Study) also failed 
to show a significant difference between active and control groups in the number of patients 
reporting a 50% reduction in visual analogue scores but did find a significant difference in 
those receiving at least a 30% reduction. 10 
Given these varied results taken together with the invasive nature of the treatment and a 
relatively high cost, it is crucial that outcome predictors are identified.  Although various 
predictors have been proposed no long-term cohorts have looked at this issue. 
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METHODS 
Patients 
One hundred patients with medically refractory chronic headache disorders who had 
undergone ONS at the National Hospital for Neurology and Neurosurgery, Queen Square, 
London, UK between February 2007 and June 2014 were identified from a prospectively 
completed clinical database.  All patients were offered ONS under the supervision of our 
institution’s Clinical Effectiveness Supervisory Committee (CESG) with arrangements for 
clinical governance, consent and audit in place.  The procedure was provided as a 
“humanitarian intervention” and ethics board approval for data collection and publication 
was granted by Northwick Park Hospital Research Ethics Committee, Hampstead, London, 
UK. 
All patients were seen by and operated upon by a single multidisciplinary specialty headache 
clinic and were diagnosed according to the International Classification of Headache 
Disorders 2nd Edition.11  All patients had failed to respond to multiple prophylactic 
medications from several different classes.  A failed trial was defined as an unsatisfactory 
response, development of intolerable side effects or valid contraindication to the use of the 
drug.  All patients with a diagnosis of medication overuse had undergone a period of 
medication withdrawal to exclude medication overuse headache.11  All patients had received 
a greater occipital nerve (GON) block, either unilateral or bilateral depending on pain 
laterality.  Greater occipital nerve block was conducted using 2ml 2% lidocaine and 80mg 
depomedrone injected in the suboccipital area at a point lying on the medial third of a line 
drawn between the inion and mastoid process12.  Response to GON block was defined as a 
patient reporting a 50% or more improvement in headache frequency or severity lasting at 
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least two weeks.  Response to GON block was not used, however, as an inclusion criteria 
for ONS insertion.  Intractability is defined by the International Headache Society (IHS) for 
chronic migraine and chronic cluster headache13 but not for short lasting unilateral 
neuralgiform headache attacks or hemicrania continua, therefore, local criteria were 
developed (Table 1).  
This study only included patients with a single chronic headache type. Patients with multiple 
headache phenotypes were not considered as the inclusion of multiple outcomes from a 
single patient may have caused bias in efficacy data. One hundred patients were identified 
with a single chronic headache disorder.  
 
Surgical Procedure 
Subjects were implanted with devices from Medtronic Inc. (Minneapolis, MN, USA) (91 
patients) and St Jude Medical (Plao, TX, USA) (9 patients).  ONS systems were implanted 
as described elsewhere and bilateral ONS electrodes were placed in all patients.7 Trial 
stimulation was not employed as our unit data does not feel that current data supports it as a 
useful indicator of long-term outcome.  Implantable pulse generators (IPG) were placed in 
the abdomen or subclavicular regions.        
Patients were provided with remote controls to allow adjustment of stimulation amplitude 
and were asked to use continuous tonic stimulation.  Polarity of the electrodes was adjusted 
to achieve comfortable bilateral paresthesia in the occipital region.  Medications were 
changed as needed during follow-up at the discretion of the treating specialist.  Further 
details on the programming values used are available in papers from this group on the 
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outcomes of ONS in chronic migraine7, chronic cluster headache14, short-lasting unilateral 
neuralgiform headache attacks (accepted but awaiting publication) and hemicrania 
continua15. 
 
Data Collection 
The primary aim for this study was the identification of clinical predictors of response to 
ONS.  The primary outcome measure was clinical response to ONS.  Clinical response to 
ONS has not yet been defined in the literature, however, based on previous publications on 
ONS for chronic headache3, 5, 7-10, 16 and IHS recommendations for outcome measures for 
CM17 we defined a positive response to ONS as being a 50% or more reduction in either 
attack frequency (for CCH and short lasting unilateral neuralgiform headache attacks) or in 
moderate-to-severe  headache days (for CM and HC).  Moderate-to-severe  headache days 
were defined as days with pain scoring a peak intensity of at least four on the verbal rating 
scale (VRS) lasting at least four hours or of any duration or intensity if painkillers were 
taken.17  Patients were asked to complete a headache diary recording the frequency, severity 
(on a verbal rating scale [VRS; 0=no pain to 10= extreme pain]) and duration of headaches 
for four weeks prior to implant and for two weeks prior to each follow-up visit.  Diaries were 
used to calculate a mean daily attack frequency or monthly moderate-to-severe  headache 
days as appropriate. 
Secondary outcome measures included response rates in individual headache phenotypes, 
and affect scores (Hospital Anxiety [HAD-A] and Depression [HAD-D] scores). 
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Data were collected prospectively from February 2007 and entered onto a clinical database 
(Microsoft Excel, Microsoft Corporation, Redmond, WA, USA).  Data collected included 
demographics, diagnosis, headache frequency, severity and duration, previous and current 
treatments, and headache characteristics. 
 
Statistics 
All statistical analyses were conducted using IBM SPSS Statistics version 22 (IBM Corp. 
Int.).  A last observation carried forward technique was used in the case of missing data.  
Descriptive statistics were summarized as appropriate.  Data is presented as mean and 
standard deviation (SD) unless otherwise stated.  All statistical tests were two-sided with a 
significance level of 95%.  Within group differences were examined using paired t-tests, 
Wilcoxon paired test or McNemar’s test as appropriate.  Testing for between group 
differences was performed using two sample t-tests, one-way ANOVA, Chi-square or 
Fisher’s exact test as appropriate.   
Binary logistic regression analysis were carried out to predict ONS outcome for the cohort 
using the following independent variables at time of implant: headache phenotype, presence 
of occipital pain (defined as any pain reported in the C2-C3 distribution), presence of co-
existing non-headache pain conditions (Supplementary Table 1), presence of severe anxiety 
or depression (defined as a score of ≥15 on HAD-A and/or HAD-D), previous response to 
greater occipital nerve (GON) block  (defined as patient reporting a 50% or more 
improvement in their headaches lasting more than 2 weeks), presence of medication overuse 
(defined as more than 10 days a month of opiates, ergots, triptans or combination-analgesics 
use or 15 days a month of simple analgesia or non-steroidal anti-inflammatory agents use in 
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those with diagnosed CM or HC) and the presence of co-existent episodic headache 
disorders.  All variables were predefined in advance of the data analysis.  
 
RESULTS 
Baseline 
One hundred patients with a single chronic headache diagnosis underwent ONS implantation 
between February 2007 and June 2014.  The mean (SD) age at implant was 48.46 (12.26) 
years and 55% of the group was male.  The cohort consisted of 35 patients with CM, 33 
patients with CCH, 20 with short lasting unilateral neuralgiform headache attacks and twelve 
with HC.  Demographics of the whole group are presented in Table 2. 
 
Final Follow Up 
The mean (SD) time from implant to final follow-up was 45.60 (21.69) months with a range 
of 13 months to 8 years. (Table 2). At the time of final follow–up, six patients had had their 
ONS devices permanently removed (five for lack of efficacy and one due to intractable pain 
over the neck and chest leads).   Of those removed for lack of efficacy two were  CM patients 
(removed at two years and at 11 months) and three were CCH patients (removed at two years 
at 14 months and at nearly five years).  The one removed due to intractable pain over the 
leads was a CCH patient (removed at 20 months). 
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Response Rate 
A positive response to ONS was defined as a 50% or more reduction in a patient’s mean 
daily attack frequency or monthly moderate-to-severe  headache days.  The response rate of 
the whole cohort was 48%.  The response rate of the individual phenotypes was 28.5% 
(n=10) for CM, 54.5% (n=18) for CCH, 75% (n=15) for short lasting unilateral neuralgiform 
headache attacks and 41.7% (n=5) for HC.   
 
Univariable associations with outcome 
Baseline characteristics assessed for association with response to ONS are shown in Table 
3.  Variables associated with a positive outcome to ONS were CCH [OR 2.56 (95%CI 1.05, 
6.24)] (p=0.021) and the presence of short lasting unilateral neuralgiform headache attacks 
[OR 4.27 (95% CI 1.28, 15.07)] (p=0.007).  Variables associated with a negative outcome 
to ONS were the presence of CM [OR 0.28 (0.10,0.74)] (p=0.004) and occipital head pain 
[OR 0.26 (95%CI 0.10, 0.64)] (p=0.001). 
 
Multivariable associations with outcome 
Short lasting unilateral neuralgiform headache attacks were associated with increased 
likelihood of response when compared to CM [OR 6.71 (95% CI 1.49, 30.05)] (p=0.013).  
A previous positive response to GON block was associated with a positive response to ONS 
[OR 4.22 (95% CI 1.35, 13.21)] (p=0.014).  A reduced likelihood of response was associated 
with the presence of occipital pain [OR 0.27 (95%CI 0.09, 0.76)] (p=0.014) and severe 
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anxiety and/or depression at the time of implant [OR 0.32 (95%CI 0.11, 0.91)] (p=0.032) 
(Table 3). 
 
DISCUSSION 
Identifying predictors of response to ONS is important due to the high cost and invasiveness 
of the procedure.  This is the first study to specifically examine predictors for ONS using 
multivariate analysis to identify clinical variables associated with response to ONS.  
Predictors were selected due to their use as inclusion/exclusion criteria in previous studies 
of ONS or on the basis of previous suggestions of their association with headache and 
chronic pain outcome.8-10, 18-20   
Univariate analysis showed both CCH and short lasting unilateral neuralgiform headache 
attacks are associated with a two and four times increased likelihood of response 
respectively, whereas CM was associated with 72% reduced likelihood of response.  
Presence of occipital pain was another negative predictor showing a 74% reduced likelihood 
of response. 
Multivariate analysis suggested that, when compared to CM, short lasting unilateral 
neuralgiform headache attacks had a nearly seven times increased likelihood of positive 
response to ONS.  The multivariate analysis also suggested that a previous positive response 
to GON block was associated with a four times higher likelihood of positive outcome.  
Negative predictors again included the presence of occipital pain (73% less likely to respond) 
but also the presence of severe anxiety and/or depression with a 68% reduction in likelihood 
of response. 
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The negative association between the presence of occipital pain and outcome is of significant 
interest as it has been an inclusion criterion in controlled studies of ONS.  If it is a negative 
predictor this may explain why the results of studies were less than convincing.  The potential 
reasons for occipital pain predicting poor outcome are unclear.  Although one could 
speculate that those with posterior head pain may be more prone to painful stimulation 
effects leading them to be intolerant of stimulation this was not borne out in subgroup 
analysis.  Our work suggests that there are other reasons, as yet unaccounted for, as to why 
occipital pain may influence ONS outcome. 
It is acknowledged that depression and anxiety can be associated with worsening pain or an 
unimproved situation despite treatment. 21  Mood disorders and catastrophising have been 
found to be predictive of a poor outcome to lower back pain22 and interestingly to spinal cord 
stimulation for lower back pain.23  The reasons for this association are not clear, as the 
psychosocial model of chronic pain is relatively complex.  However, specific to 
neurostimulation, functional imaging studies report ONS affecting higher pain centers such 
as the insula and anterior cingulate regions2 both of which also have a role in emotional 
processing and mood.  There may, therefore, be a neurochemical basis for the lower response 
rates due to these centres influencing anti-nociceptive processing in those with mood 
disorders.  Current recommendations stress the importance of psychological input in the 
assessment and management of neurostimulation candidates and our data suggests that this 
is vital. 
It is not surprising to observe CM associated with a lower likelihood of response (as seen in 
the univariate analysis) as this appears to be the case in the published trials and open-label 
data.  From our own experience, we have seen that short lasting unilateral neuralgiform 
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attack disorders seem to respond well to ONS and this observation seems to be supported in 
the analysis.  Again, our experience suggests that CCH has a higher response rate than CM.  
Univariate analysis showed that CCH was associated with increased likelihood of response 
but this was not maintained in the multivariate model.  However, the confidence interval of 
the odds ratio for CCH response suggest that the true population response lies between a 
35% reduced likelihood of response and an eight times increased likelihood.  Clinically, the 
population estimate suggests a trend for chronic cluster responding better than chronic 
migraine although statistical significance is not reached.  The reason for the observation of 
a lower response rate in CM is not yet easily explained.  Although it is easy to speculate that 
the response rate to all phenotypes should be similar given ONS works on the same shared 
pathway (trigeminocervical complex linking to the trigeminovascular system) in all, we 
know from clinical experience of other pharmaceutical agents that this concept is too simple.  
As of yet, the exact mechanism of ONS in different phenotypes is unknown and in fact, new 
insights into the possible pathogenesis and the pain processing pathways involved in each 
phenotype is constantly evolving.  For example, the concept that hypothalamic activation 
was only seen in TACs and thus had to be the pathway of major importance has recently 
been called into question by the work of Schulte et al. who described hypothalamic activation 
in patients with migraine more than with controls suggesting that the hypothalamus has a 
crucial rule in pain generation in both migraine and TACs.24  However, to explain why 
response rates are so different raises questions regards the relative importance of the different 
pathways in the different phenotypes, the possible pathways selectively targeted by ONS in 
each phenotype or indeed the possibility of differences in the pathways modulated in 
responders and non-responders to ONS. 
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The predictive value of GON block in ONS was initially raised by Weiner and Reed in 
1999.18 The ONSTIM trial used a response to GON block as an inclusion criterion but sub 
analysis did not find clear evidence to support a link between response to greater occipital 
nerve block and ONS.8  Schwedt et al. examined 13 patients responses to GON block and 
ONS for a variety of headache conditions and concluded that response to nerve block did 
not predict ONS outcome. 19  However, in their cohort, a response to the nerve block was 
defined as a 50% or more reduction in headache severity lasting for at least 24 hours, a much 
less stringent response than defined in our analysis, which required a response lasting at least 
2 weeks.   A recent systematic review of open-label data on this issue found no predictive 
validity of GON block in the outcome of ONS in CM trials but could only find data on 45 
patients out of the 133 included in studies.25  In that review, the authors state that response 
to ONS was seen in those reporting no GON block benefit and also, vice versa, that some 
patients with a previous response to GON block failed to improve with ONS.  The authors 
suggest there is a need for a prospective study on the predictive value of GON block.  The 
reason for conflicting data in our cohort may include the use of a multivariate model, single 
and stricter definitions of headache response and GON block response rate.   
Other potential factors suggested as predictive of ONS outcome have included previous 
response to  transcutaneous (TENS)26 or percutaneous nerve stimulation (PENS) 27 of the 
occipital region and perceived sensation over the occipital region during ONS treatment28, 
29.  Although the open-label study by Nguyen et al. suggested that a “good to very good” 
response to TENS prior to ONS was associated with a significantly higher reduction in pain 
scores after three years, their data is somewhat flawed.  The outcome to TENS was judged 
by patient’s subjective estimate only and given that only those with a good to very good 
subjective response to TENS were implanted with ONS there is no real negative comparator.  
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Kinfe and colleagues used a more robust protocol to examine a group of 12 patients with 
chronic refractory headache treated with PENS prior to ONS implant (with all patients 
receiving both treatments).  This group concluded that pre-surgical PENS did not identify 
ONS responders.  It is commonly accepted that in order to achieve response to ONS, 
stimulation programs should be employed that provide a perceptible level of paresthesia over 
the occiput.  Although no large-scale studies have been employed to discover which program 
parameters provide optimum results there have been small series reporting on both the spread 
of paresthesia and the use of subthreshold (i.e. non-perceivable) stimulation.  Slotty et al 
compared a group of CM patients and their reported response to ONS as they cycled through 
treatments with “effective stimulation”, “subthreshold stimulation” and no stimulation.28  
Although they concluded that paresthesia is not an absolute requirement of response, they 
did find that suprathreshold stimulation was associated with better outcomes.  In another 
series looking at the paresthesia induced during ONS, Trentman et al undertook sensory 
mapping of patients undergoing ONS.29  Although they report that the majority of patients 
felt paresthesia in the occipital region they also recorded stimulation at more distant sites, 
albeit rarely.  However, the group did not correlate location of paresthesia with outcome 
although this would be an interesting extension that would help to guide programming 
technique. 
Preventative treatments, including ONS, have been postulated to be less effective in the 
presence of medication overuse.30  However, randomized trials of topiramate and 
onabotulinumtoxinA have shown these to be efficacious in CM even in those overusing acute 
medication.31, 32  An important point to consider is the subtle but important difference 
between the overuse of acute medication and medication overuse headache. All our patients 
were screened for medication overuse headache and only implanted if they failed to improve 
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following medication detoxification.  Our results support the call for further discussions 
around the classification of CM with “medication overuse” versus “medication overuse 
headache” and their impact on treatment outcomes. 
Half of our group experienced a positive response to ONS at a mean follow-up time of 45.49 
months. A major issue in comparing our data with that from other centers is the huge 
variability in outcome measures used in the literature.  Although for CCH most centers quote 
reduction in daily attack frequency, some have also used reduction in pain scores or patient 
estimates of overall improvement.  For CM there is a far greater variety of published 
outcomes including changes in pain scores, headache days, migraine days, moderate-to-
severe  headache days, duration of headache and MIDAS.33  Our primary outcome measures 
were based on recommendations from the International Headache Society. 
Given the prospective nature of the study, the main weakness is the lack of a placebo control.  
However, in line with previous publications and against a pure placebo response, our group 
showed a delay to maximum reported improvement in the order of months and worsening of 
pain when the device was switched off for any period.  More importantly, the placebo rate 
of ONS in the controlled trials on CM are quoted at 6%, 17% and 20% - all below the 
outcome seen in our cohort.8-10  Chronic daily headache does remit to less than 15 days a 
month in a proportion of subjects followed in longitudinal studies with a one to four year 
remission rate of 33-65%.34-36 However, returning to low frequency episodic headache (less 
than one a week) is less common (14%).35  These studies were conducted in the community 
and it is likely subjects were different from sufferers in specialist headache clinics.  The 
patient populations seen in the ONS specialist clinics are also progressively negatively 
selected by treatment response so as to represent those truly chronic and unremitting cases 
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from the initial persistent chronic daily headache sufferers in the general population.  
Therefore, we argue that natural history alone would not explain the improvement seen 
following ONS in this cohort.   
In conclusion, ONS appears to be an effective treatment in highly intractable chronic 
headache patients.  Short lasting unilateral neuralgiform disorder was associated with a better 
outcome than chronic migraine and a positive response to GON block was also associated 
with an increased likelihood of response to ONS.  The presence of severe anxiety and/or 
depression and the presence of occipital pain were both found to be associated with a reduced 
likelihood of response.  Predictors of outcome in ONS are crucial in identifying those 
patients most likely to benefit from costly and invasive procedures.  More work is needed to 
validate these predictors and identify other factors, both clinical and stimulation related, that 
might be useful in predicting response to ONS. 
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Chronic migraine – failure of at least 4 classes, with three from 1-4 
1 – β-blockers 
2-Anticonvulsants 
3-Calcium channel blockers 
4-Tricyclic antidepressants 
5-Other treatments with at least one positive randomised controlled trial 
6-NSAID 
7-Metabolic enhancers (co-enzyme Q10/Vitamin B12) 
Chronic cluster headache – failure of at least 4 classes, with two from 1-4 
1-Verapamil 
2-Lithium 
3-Methysergide 
4-Melatonin 
5-Topiramate 
6-Gabapentin 
Short lasting unilateral neuralgiform headache attacks – failure of all five of the 
following 
1-Lamotrigine 
2-Topiramate 
3-Gabapentin 
4-Pregabalin 
5-One of either Carbamazepine or Oxcarbazepine 
Hemicrania Continua – failure of at least five of the following including 1 
1-Indometacin* 
2-Cyclo-oxygenase II Inhibitors 
3-Verapamil 
4-Topiramate 
5-Melatonin 
6-Gabapentin 
7-Pregabalin 
8-Flunarazine 
 
 Table 1: Intractable Headache 
Local guidelines used for the diagnosis of medically intractable chronic headache (Chronic 
migraine and Chronic cluster headache guidelines as per Goadsby et al.11; Short lasting 
unilateral neuralgiform headache attacks as per Lambru et al.6) 
*Failure of response to indometacin defined as positive response of headache attacks (thereby 
confirming diagnosis of hemicrania continua) to indometacin but intolerable side effects 
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 Whole Group 
(n=100) 
Responders 
(n=48) 
Non-Responders 
(n=52) 
p-value 
Age (years) 
Mean (±SD) 
Range 
 
48.46 (±12.26) 
20-74 
 
48.77 (±12.73) 
20-74 
 
48.17 (±11.93) 
26-74 
 
0.809 
Gender 
Male: n (%) 
Female: n (%) 
 
55 (55%) 
45 (45%) 
 
26 (54.2%) 
22 (45.8%) 
 
29 (55.8%) 
23 (44.2%) 
 
0.872 
Co-existent pain condition* 
Yes: n (%) 
 
31 (31%) 
 
17 (35.4%) 
 
14 (26.9%) 
 
0.359 
Phenotype: n (%) 
CM  
CCH 
SUNCT/SUNA 
HC 
 
35 (35%) 
33 (33%) 
20 (20%) 
12 (12%) 
 
10 (20.8%) 
18 (37.5%) 
15 (31.3%) 
5 (10.4%) 
 
25 (48.1%) 
15 (28.8%) 
5 (9.6%) 
7 (13.5%) 
0.008** 
Co-existent episodic headaches: n(%) 
Yes: n(%) 
 
23 (23%) 
 
14 (29.1%) 
 
9 (17.3%) 
 
0.159 
EM 
ECH 
Idiopathic Stabbing Headache 
16 (16%) 
3 (3%) 
4 (4%) 
9 (18.7%) 
2 (4.2%) 
3 (6.2%) 
7 (13.5%) 
1 (1.9%) 
1 (1.9%) 
 
Duration of chronic headache (years) 
Mean (±SD) 
Range 
 
10.18 (±8.98) 
2-48 
 
9.81 (±8.62) 
2-46 
 
10.52 (±9.37) 
2-48 
 
0.696 
Pain free days 
Yes: n(%) 
 
11 (11%) 
 
6 (12.5%) 
 
5 (9.6%) 
 
0.645 
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Number of preventatives tried prior to ONS   
Mean (SD) 
Range 
 
9.92 (±3.38) 
4-21 
 
10.04 (±3.69) 
5-20 
 
9.81 (±3.10) 
4-21 
 
0.732 
Previous response to GON block*** 
Yes: n(%) 
 
26 (26%) 
 
16 (33.3%) 
 
10 (19.2%) 
 
0.108 
Severe anxiety or depression (≥15 on the HAD-A or 
HAD-D scale) 
Yes: n(%) 
 
 
35 (35%) 
 
 
 
13 (27.1%) 
 
 
22 (42.3%) 
 
 
0.111 
Medication overuse  
(As per ICHD-3beta criteria) 
Yes: n(%) 
 
 
19 (19%) 
 
 
11 (22.9%) 
 
 
8 (15.4%) 
 
 
0.337 
Follow-up since implant (months) 
Mean (±SD) 
Range 
 
 45.60(±21.69) 
15-97 
 
46.16 (±21.50) 
2-92 
 
44.86 (±22.44) 
13-97 
 
0.768 
 
SD, Standard deviation 
CCH, Chronic cluster headache; CM, Chronic migraine; ECH, Episodic cluster headache; EM, Episodic migraine; GON, greater occipital nerve; HAD-A, 
Hospital Anxiety and Depression Score – Anxiety component; HAD-D, Hospital Anxiety and Depression Score – Depression component; HC, Hemicrania 
Continua; ICHD-3beta, International Classification of Headache Disorders 3 beta edition; ONS, Occipital nerve stimulator; SUNA, Short lasting unilateral 
neuralgiform headache attacks with autonomic features; SUNCT, Short lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing;  
*Co-existent pain conditions: As detailed in Supplementary table 1; **P value<0.05;  *** Response to GON block defined as patient reporting a 50% or more 
improvement in headache frequency or severity lasting at least 2 weeks 
 
TABLE 2: Patient Demographics and Baseline Clinical and Headache Characteristics. 
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Variable  Univariable Analysis 
Odds Ratio (95% CI) 
p-value Multivariable Analysis 
Odds Ratio (95% CI) 
p-value 
Headache 
phenotypes  
 
Chronic Migraine 
Chronic Cluster Headache 
Chronic SUNCT/SUNA 
HC 
0.28 (0.10,0.74) 
2.56 (1.05, 6.24) 
4.27 (1.28, 15.07) 
0.74 (0.18, 2.90) 
0.004* 
0.021* 
0.007* 
0.640 
Comparator 
2.32 (0.64, 8.43) 
6.71 (1.49, 30.05) 
1.38 (0.29, 6.52) 
 
0.199 
0.013* 
0.679 
Presence of 
medication overuse 
Yes 1.63 (0.53,5.04) 0.337 1.45 (0.34, 6.07) 0.606 
Presence of non-
headache chronic 
pain condition 
Yes 1.48 (0.58,3.80) 0.359 1.65 (0.58, 4.65) 0.342 
Severe Anxiety or 
Depression (HAD-
A/HAD-D ≥15) 
Yes 0.50 (0.20, 1.2) 0.111 0.32 (0.11, 0.91) 0.032* 
Prior response to 
GON Block 
Yes 2.10 (0.77, 5.79) 0.108 4.22 (1.35, 13.21) 0.013* 
Occipital Pain Yes 0.26 (0.10, 0.64) 0.001* 0.27 (0.09, 0.76) 0.014* 
Co-existing episodic 
headache disorder 
Yes 1.96 (0.69, 5.66) 0.159 1.36 (0.39, 4.76) 0.626 
GON, greater occipital nerve; HC, Hemicrania Continua; SUNA, Short lasting unilateral neuralgiform headache attacks with autonomic features; SUNCT, 
Short lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing;  
 
Table 3: Results of univariate and multivariate analysis 
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EDS, Ehlers-Danlos Syndrome 
 
Supplementary Table 1: The non-headache related pain conditions reported by the 
patient cohort. 
Pain Syndrome Number 
Reporting 
Musculoskeletal Conditions: 
Back Pain 
Cervical Spondylosis  
Osteoarthritis 
EDS-Hypermobility Type 
16 
10 
2 
3 
1 
Fibromyalgia (with/without Chronic Fatigue) 7 
Gastrointestinal Conditions: 
Irritable Bowel Syndromes 
Diverticulitis 
12 
10 
2 
Gynaecological Conditions: 
Endometriosis 
2 
2 
Neurological Conditions: 
Sciatica 
Neuropathy 
9 
2 
7 
